FIGURE

Fig. 1

ID

ZDB-FIG-250327-1

Publication

Hua et al., 2025 - Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Osimertinib-resistant NSCLC cell lines were established, and the IC50 values of osimertinib and anlotinib were determined. An MTT assay was used to explore cell viability in (A) H1975 and H1975-OR cells and (B) PC9 and PC9-OR cells treated with different concentrations of osimertinib. A CCK-8 assay was conducted to explore the proliferative capacities of (C) H1975 and H1975-OR cells and (D) PC9 and PC9-OR cells. An MTT assay was conducted to measure cell viability in (E) H1975 and H1975-OR cells and (F) PC9 and PC9-OR cells treated with different concentrations of anlotinib. P values were calculated using two-way ANOVA analysis; ***, P<0.001. OD, optical density; NSCLC, non-small cell lung cancer; IC50, half-maximal inhibitory concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide; CCK-8, Cell Counting Kit-8; ANOVA, analysis of variance.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Transl Lung Cancer Res